We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Aventis’ Optipen Pro insulin pen injection system has generated more than 1,000 technical complaints in the U.K., prompting the Medicines and Healthcare products Regulatory Agency (MHRA) to issue an alert.
The U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) is urging devicemakers and healthcare providers to report adverse events within 24 hours.